It’s a very interesting one, especially given the valuation discount to Givaudan/Symrise or DSM-Firmenich. However the lack of liquidity and family ownership have really not helped. After the bump during covid, the stock has meaningfully under-performed being down -12% over the last five years while GIVN is up almost 40%.
Thank you for having me on the podcast, it was a blast :)
It’s a very interesting one, especially given the valuation discount to Givaudan/Symrise or DSM-Firmenich. However the lack of liquidity and family ownership have really not helped. After the bump during covid, the stock has meaningfully under-performed being down -12% over the last five years while GIVN is up almost 40%.